SOOLIKANA NEI FOR WHEEZING IN CHILDREN

Phase II Non Randomised Clinical Study On Sooli Kanam (Bronchial Aathma) In Children WITH THE EVALUATION OF SIDDHA TRIAL DRUG SOOLI KANA NEI

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/11/047659

Enrollment

Registered

2022-11-25

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

Intervention1: Sooli Kana Nei: Sooli Kana Nei Dosage 2-5 grams bd Duration 14days Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Cough without expectoration Dyspnea Running nose Chest tightness Wheezing

Exclusion criteria

Exclusion criteria: Primary complex Hypersensitivity Pneumonitis Lung Abscess Cystic fibrosis Bronchiolitis

Design outcomes

Primary

Measure	Time frame
It is assesed by reduction in clinical symptoms and Modified Asthma Scale before and after treatmentTimepoint: 14 days	—

Secondary

Measure	Time frame
It is assessed by comparing the safety parameters before and after treatment. Along with this investigational changesof reduction in ESR level, Eosinophil counts, WBC and increase level of HBTimepoint: 14 days	—

Countries

India

Contacts

Public ContactDr Komalesvaran R

Government Siddha medical college

malarvizhiisha@gmail.com9444487063

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026